This Article Full Text Full Text (PDF) All Versions of this Article: 39/5/1629    most recent STROKEAHA.107.485938v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Takasawa, M. Articles by Baron, J.-C. PubMed PubMed Citation Articles by Takasawa, M. Articles by Baron, J.-C. Related Collections Acute Cerebral Infarction Imaging PET and SPECT

(Stroke. 2008;39:1629.)
© 2008 American Heart Association, Inc.

Topical Review

Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke

Masashi Takasawa, MD, FJSIM, PhD; Ramez Reda Moustafa, MD, MRCP Jean-Claude Baron, MD, FRCP, FMedSci

From the Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, UK.

Correspondence to Professor Jean-Claude Baron, University of Cambridge, Department of Clinical Neurosciences, Addenbrooke’s Hospital, Box 83, Cambridge CB2 2QQ, UK. E-mail jcb54{at}cam.ac.uk

Abstract

Background and Purpose— Nitroimidazole imaging is a promising contender for noninvasive in vivo mapping of brain hypoxia after stroke. However, there is a dearth of knowledge about the behavior of these compounds in the various pathophysiologic situations encountered in ischemic stroke. In this article we report the findings from a systematic review of the literature on the use of the nitroimidazoles to map hypoxia after stroke.

Summary of Review— We describe the characteristics of nitroimidazoles as imaging tracers, their pharmacology, and results of both animal and clinical studies during and after focal cerebral ischemia. Findings in brain tumors are also presented to the extent that they enlighten results in stroke. Early results from application of kinetic modeling for quantitative measurement of tracer binding are briefly discussed.

Conclusions— Based on this literature review, nitroimidazole hypoxia imaging agents are of considerable interest in stroke because they appear, both in animal models and in humans, to specifically detect the severely hypoxic viable tissue, but not the reperfused nor the necrotic tissue. To fully realize this potential in stroke, however, formal validation by concurrent measurement of tissue oxygen tension, together with development of novel ligands with faster distribution kinetics, faster clearance from normal tissue, and well-defined trapping mechanisms, are important goals for future investigations.

Supplemental Appendix